hellotayssir/FinQA_TAT-QA_financial_finetuning_dataset huggingface dataset:
The following table summarizes the activity related to the Company's gross unrecognized tax benefits from April 1, 2016 to March 31, 2019 (amounts in millions):
As of March 31, 2019 and March 31, 2018, the Company had accrued interest and penalties related to tax contingencies of $88.1 million and $80.8 million, respectively. Interest and penalties charged to operations for the years ended March 31, 2018 and 2017 related to the Company's uncertain tax positions were $5.4 million and $5.8 million, respectively. Previously accrued interest and penalties that were released during the year ended March 31, 2019 were $37.5 million.
The total amount of gross unrecognized tax benefits was $763.4 million and $436.0 million as of March 31, 2019 and March 31, 2018, respectively, of which $664.4 million and $436.0 million is estimated to impact the Company's effective tax rate, if recognized. The Company estimates that it is reasonably possible unrecognized tax benefits as of March 31, 2019 could decrease by approximately $50.0 million in the next 12 months. Positions that may be resolved include various U.S. and non-U.S. matters.
Table:
 |  | Year Ended March 31, | 
 | 2019 | 2018 | 2017
Beginning balance | $436.0 | $398.5 | $220.7
Increases related to acquisitions | 329.7 | — | 193.3
Decreases related to settlements with tax authorities | (8.3) | (0.1) | (11.7)
Decreases related to statute of limitation expirations | (16.2) | (10.9) | (7.6)
Increases related to current year tax positions | 27.8 | 30.3 | 26.3
Increases (decreases) related to prior year tax positions | (5.6) | 18.2 | (22.5)
Ending balance | $763.4 | $436.0 | $398.5


Question: What were the Increases related to acquisitions in 2017?
Answer: 193.3
Liquidity and Capital Resources
Our principal sources of liquidity are cash and cash equivalents, investments and accounts receivable. The following table shows net cash provided by operating activities, net cash used in investing activities, and net cash provided by (used in) financing activities for the years ended March 31, 2019, 2018 and 2017:
In November 2015, we raised net proceeds of $68.3 million in our initial public offering after deducting underwriting discounts and commissions and offering expenses paid by us. In the years ended March 31, 2019, 2018 and 2017, we incurred operating losses of $1.2 million, $7.0 million and $10.4 million, respectively. While we expect to generate an operating loss in the year ending March 31, 2020, we expect to continue to generate positive cash flows from operating activities.
In the year ending March 31, 2020, we plan to continue to invest in the development and expansion of our Mime | OS™ platform to improve on our existing solutions in order to provide more capabilities to our customers. Investments in capital expenditures in the year ended March 31, 2019 were $28.8 million of which $25.8 million related to the expansion of our grid architecture.
We expect fiscal year 2020 capital expenditures to increase significantly as we expect to incur one-time costs related to the build out and expansion of facilities in the U.K. and other locations and additional data center expansion primarily in the U.S.
As of March 31, 2019 and 2018, we had cash, cash equivalents and investments of $173.5 million and $137.2 million, respectively. Based on our current operating plan, we believe that our current cash and cash equivalents, investments and operating cash flows will be sufficient to fund our operations for at least the next twelve months. Our future capital requirements may vary materially from those planned and will depend on certain factors, such as our growth and our operating results.
If we require additional capital resources to grow our business or to acquire complementary technologies and businesses in the future, we may seek to sell additional equity or raise funds through debt financing or other sources. We may also seek to invest in or acquire complement ary businesses, applications or technologies, any of which could also require us to seek additional equity or debt financing.
We cannot provide assurance that additional financing will be available at all or on terms favorable to us. We had no material commitments for capital expenditures as of March 31, 2019 or 2018.
Table:
 |  | Year ended March 31,  | 
 | 2019 | 2018 | 2017
 |  | (in thousands) | 
Net cash provided by operating activities | $66,235 | $46,412 | $32,514
Net cash used in investing activities | (121,324) | (35,019) | (84,615)
Net cash provided by (used in) financing activities | 116,985 | 13,156 | (332)


Question: In which year was Net cash provided by (used in) financing activities less than 25,000 thousands?
Answer: 2018, 2017
Calculation: locate and analyze Net cash provided by (used in) financing activities in row 6
6. Goodwill and Other Intangible Assets
The Company completed its annual impairment test for goodwill and indefinite-lived intangible assets during the fourth quarter of fiscal year 2019 and determined the fair values of the reporting units and the indefinite-lived intangible assets were in excess of the carrying values and that no impairment existed as of the date of the impairment test.
The following table presents the changes in goodwill allocated to the Company’s reportable segments, Electronics Manufacturing Services (“EMS”) and Diversified Manufacturing Services (“DMS”), during the fiscal years ended August 31, 2019 and 2018 (in thousands):
(1) Includes $8.2 million of goodwill reallocated between DMS and EMS during fiscal year 2018.
Table:
 | EMS | DMS | Total
Balance as of August 31, 2017 | $52,574 | $555,610 | $608,184
Acquisitions and adjustments(1) | 30,763 | (8,186) | 22,577
Change in foreign currency exchange rates | (667) | (2,349) | (3,016)
Balance as of August 31, 2018 | 82,670 | 545,075 | 627,745
Change in foreign currency exchange rates | (702) | (4,788) | (5,490)
Balance as of August 31, 2019 | $81,968 | $540,287 | $622,255


Question: What is the difference in Acquisitions and adjustments in fiscal 2018 between EMS and DMS?
Answer: 38949
Calculation: 30,763-(-8,186)
A summary of the option activity as of May 26, 2019 and changes during the fiscal year then ended is presented below:
We recognize compensation expense using the straight-line method over the requisite service period, accounting for forfeitures as they occur. During fiscal 2017, we granted 1.1 million stock options with a weighted average grant date fair value of $6.12 per share. The total intrinsic value of stock options exercised was $7.9 million, $15.8 million, and $29.8 million for fiscal 2019, 2018, and 2017, respectively. The closing market price of our common stock on the last trading day of fiscal 2019 was $28.83 per share.
Compensation expense for stock option awards totaled $2.2 million, $4.2 million, and $6.2 million for fiscal 2019, 2018, and 2017, respectively, including discontinued operations of $0.2 million for fiscal 2017. Included in the compensation expense for stock option awards for fiscal 2019, 2018, and 2017 was $0.2 million, $0.4 million, and $0.9 million, respectively, related to stock options granted by a subsidiary in the subsidiary's shares to the subsidiary's employees. The tax benefit related to the stock option expense for fiscal 2019, 2018, and 2017 was $0.5 million, $1.4 million, and $2.4 million, respectively.
At May 26, 2019, we had $0.2 million of total unrecognized compensation expense related to stock options that will be recognized over a weighted average period of 0.1 years.
Cash received from stock option exercises for fiscal 2019, 2018, and 2017 was $12.4 million, $25.1 million, and $84.4 million, respectively. The actual tax benefit realized for the tax deductions from option exercises totaled $2.3 million, $5.3 million, and $19.5 million for fiscal 2019, 2018, and 2017, respectively.
Table:
Options | Number of Options (in Millions) | Weighted Average Exercise Price | Average Remaining Contractual Term (Years) | Aggregate Intrinsic Value (in Millions)
Outstanding at May 27, 2018 | 5.1 | $28.11 |  | 
Exercised | (0.6) | $20.75 |  | $7.9
Expired | (0.1) | $29.84 |  | 
Outstanding at May 26, 2019 | 4.4 | $29.00 | 5.47 | $9.9
Exercisable at May 26, 2019 | 4.1 | $28.38 | 5.32 | $9.9


Question: How many options were exercisable as of May 26, 2019?
Answer: 4.1
Manoj Shetty
(1) Represents accelerated vesting of 20,687 stock options. Pursuant to Mr. Shetty's stock option agreement (January 17, 2019), if Mr.
Shetty’s employment is terminated without cause or for good reason within six months following a “change in control”, he will become
immediately vested in all outstanding unvested stock options, and all of Mr. Shetty’s outstanding options shall remain exercisable in
accordance with their terms, but in no event for less than 90 days after such termination
(2) Represents accelerated vesting of 8,107 unvested performance restricted stock units. Pursuant to Mr. Shetty's performance restricted
stock unit agreement (dated January 17, 2019), if Mr. Shetty’s employment is terminated without cause or for good reason within six
months following a “change in control” or if Mr. Shetty's employment is terminated due to death or total disability, all non-vested units
shall accelerate and be vested as of the date of termination.
Table:
Type of Payment | Termination by Systemax without “Cause” or Resignation by Employee for “good reason” ($) | Termination Due to Death or Total Disability ($) Termination Due to Death or Total Disability ($) Termination Due to Death or Total Disability ($) | Change In Control Only ($) | Termination by Systemax without “Cause” or Resignation by Employee for “good reason” within a certain period of time following a Change in Control ($)
Cash Compensation (Salary & Non-Equity Incentive Compensation Cash Compensation (Salary & Non-Equity Incentive | - | - | - | -
Value of Accelerated Vesting of Stock Option Awards | - | - | - | 74,100 (1)
Value of Accelerated Vesting of Restricted Stock Unit Awards | - | - | - | -
Value of Accelerated Vesting of Performance Restricted Stock Unit Awards | - - | 204,000 (2) | - | 204,000 (2)
Medical and Other Benefits | - | - | - | -
Total | - | 204,000 | - | 278,100


Question: What is the value of stock option awards as a percentage of the total payment for termination by Systemax without “Cause” within a certain period of time following a change in control?
Answer: 26.65
Calculation: 74,100/278,100
The funded status of the plans was as follows:
(in thousands)
Table:
 | Years Ended March 31, | 
 | 2019 | 2018
Fair value of plan assets | $90,365 | $84,718
Less: projected benefit obligations | 143,662 | 128,915
Underfunded status | $(53,297) | $(44,197)


Question: What is the average of Underfunded status between 2018 and 2019?
Answer: -48747
Calculation: ($(53,297) + $(44,197)) / 2
Results of Operations: Years Ended December 31, 2018, versus Year Ended December 31, 2017 (Amounts in thousands, except percentages and per share amounts):
Capital Resources
Long-term debt was comprised of the following:
On February 12, 2019, we entered into an amended and restated five-year Credit Agreement with a group of banks (the "Credit Agreement") to extend the term of the facility. The Credit Agreement provides for a revolving credit facility of $300,000, which may be increased by $150,000 at the request of the Company, subject to the administrative agent's approval. This new unsecured credit facility replaces the prior $300,000 unsecured credit facility, which would have expired August 10, 2020. Borrowings of $50,000 under the prior credit agreement were refinanced into the Credit Agreement. The prior agreement was terminated as of February 12, 2019.
The Revolving Credit Facility includes a swing line sublimit of $15,000 and a letter of credit sublimit of $10,000. Borrowings under the Revolving Credit Facility bear interest at the base rate defined in the Credit Agreement. We also pay a quarterly commitment fee on the unused portion of the Revolving Credit Facility. The commitment fee ranges from 0.20% to 0.30% based on the our total leverage ratio.
We have entered into interest rate swap agreements to fix interest rates on $50,000 of long-term debt through February 2024. The difference to be paid or received under the terms of the swap agreements is recognized as an adjustment to interest expense when settled.
We have historically funded our capital and operating needs primarily through cash flows from operating activities, supported by available credit under our Revolving Credit Facility. We believe that cash flows from operating activities and available borrowings under our Revolving Credit Facility will be adequate to fund our working capital needs, capital expenditures, and debt service requirements for at least the next twelve months. However, we may choose to pursue additional equity and debt financing to provide additional liquidity or to fund acquisitions.
Table:
 | As of December 31, | 
 | 2019 | 2018
Total credit facility | $300,000 | $300,000
Balance Outstanding | $99,700 | $50,000
Standby letters of credit | $1,800 | $1,940
Amount available | $198,500 | $248,060
Weighted-average interest rate | 3.25% | 3.10%
Commitment fee percentage per annum | 0.23% | 0.20%


Question: What does the Credit Agreement provide for?
Answer: revolving credit facility of $300,000, which may be increased by $150,000 at the request of the Company, subject to the administrative agent's approval.
Other Operating (Income) Expense, Net
Restructure and asset impairments primarily relate to our continued emphasis to centralize certain key functions. In addition, in 2019, we finalized the sale of our 200mm fabrication facility in Singapore and recognized restructure gains of $128 million. In 2017, we recognized net restructure gains of $15 million related to the sale of our Lexar assets; our assets associated with our 200mm fabrication facility in Singapore; and our 40% ownership interest in Tera Probe, Inc and assembly and test facility located in Akita, Japan.
Table:
For the year ended | 2019 | 2018 | 2017
(Gain) loss on disposition of property, plant, and equipment | $43 | $(96) | $(22)
Restructure and asset impairments | (29) | 28 | 18
Other | 35 | 11 | 5
 | $49 | $(57) | $1


Question: How much restructure gains did the company recognize in 2019?
Answer: $128 million
(c) Summary of Share-Based Compensation Expense
Share-based compensation expense consists primarily of expenses for stock options, stock purchase rights, restricted stock, and RSUs granted to employees. The following table summarizes share-based compensation expense (in millions):
As of July 27, 2019, the total compensation cost related to unvested share-based awards not yet recognized was $3.3 billion, which is expected to be recognized over approximately 2.8 years on a weighted-average basis.
Table:
Years Ended | July 27, 2019 | July 28, 2018 | July 29, 2017
Cost of sales—product | $90 | $94 | $85
Cost of sales—service | 130 | 133 | 134
Share-based compensation expense in cost of sales . | 220 | 227 | 219
Research and development . | 540 | 538 | 529
Sales and marketing | 519 | 555 | 542
General and administrative | 250 | 246 | 236
Restructuring and other charges | 62 | 33 | 3
Share-based compensation expense in operating expenses | 1,371 | 1,372 | 1,310
Total share-based compensation expense | $1,591 | $1,599 | $1,529
Income tax benefit for share-based compensation . | $542 | $558 | $451


Question: Which years does the table provide information for the company's share-based compensation expenses?
Answer: 2019, 2018, 2017
The tax holidays represent a tax exemption period aimed to attract foreign technological investment in certain tax jurisdictions. The effect of the tax benefits, from tax holidays for countries which are profitable, on basic earnings per share was $0.14, $0.15 and $0.13 for the years ended December 31, 2019, 2018, and 2017, respectively. These agreements are present in various countries and include programs that reduce up to and including 100% of taxes in years affected by the agreements.
The Company’s tax holidays expire at various dates through the year ending December 31, 2028. In certain countries, tax holidays can be renewed depending on the Company still meeting certain conditions at the date of expiration of the current tax holidays.
In May 2019, Switzerland voted a tax reform which cancelled all favourable tax regimes and introduced a single tax rate for all companies, which triggered the revaluation of all deferred tax assets and liabilities. Enactment of this law occurred in third quarter of 2019, which resulted in a tax benefit of $20 million. The remeasurement of deferred taxes was reconciled in the fourth quarter of 2019 to include the current year activity, which did not have a material impact on the net remeasurement.
Table:
 | Year ended December 31, 2019 | Year ended December 31, 2018 | Year ended December 31, 2017
Income tax benefit (expense) computed at statutory rate | (297) | (353) | (238)
Non-deductible and non-taxable permanent differences, net | 4 | 45 | 17
Income (loss) on equity-method investments | — | — | —
Valuation allowance adjustments | 2 | 141 | 92
Effect on deferred taxes of changes in enacted tax rates | 14 | (62) | (70)
Current year credits | 50 | 43 | 40
Other tax and credits | (51) | (20) | (36)
Benefits from tax holidays | 129 | 135 | 114
Net impact of changes to uncertain tax positions | (5) | (16) | (43)
Earnings of subsidiaries taxed at different rates | (2) | (9) | (19)
Income tax benefit (expense) | (156) | (96) | (143)


Question: What is the increase/ (decrease) in Income tax benefit (expense) from December 31, 2018 to 2019?
Answer: 60
Calculation: 156-96
Gross Profit and Gross Margin (exclusive of amortization of acquisition-related intangible assets described below)
Our gross profit by reportable segment was as follows (dollars in millions):
(1) Certain of the amounts may not total due to rounding of individual amounts. (2) Unallocated manufacturing costs are presented as a percentage of total revenue (includes expensing of the fair market value step-up of inventory of $19.6 million during 2019 and $1.0 million during 2018).
The decrease in gross profit of $265.1 million, or approximately 12%, was primarily due to the impact of the decrease in sales volume, higher fixed costs due to the expansion in our manufacturing capacity as well as the expensing of $19.6 million excess over book value of inventory, commonly referred to as the fair market value step-up, from the Quantenna acquisition.
Gross margin decreased to 35.8% during 2019 compared to 38.1% during 2018. The decrease was due to a competitive pricing environment resulting in a decline in average selling prices, higher demand for lower margin products, increased manufacturing costs due to a higher mix of external manufacturing and decreased demand for our products, as explained in the revenue section.
Table:
 | 2019 | As a % of Segment Revenue (1) | 2018 | As a % of Segment Revenue (1)
PSG | $976.0 | 35.0 % | $ 1,110.1 | 36.5 %
ASG | 794.8 | 40.3 % | 878.3 | 42.4 %
ISG | 275.4 | 36.4 % | 317.1 | 41.2 %
Gross profit for all segments | $ 2,046.2 |  | $ 2,305.5 | 
Unallocated manufacturing costs (2) | (72.6) | (1.3) % | (66.8) | (1.1) %
Total gross profit | $ 1,973.6 | 35.8 % | $ 2,238.7 | 38.1 %


Question: What is the change in gross profit from ASG from 2018 to 2019?
Answer: -83.5
Calculation: 794.8-878.3
Note 3 – Net Income per Share
Reconciliation of net income per common share:
Table:
 |  | Fiscal Year Ended | 
 | December 27, 2019  | December 28, 2018  | December 29, 2017
Numerator: |  |  | 
Net income | $24,193 | $20,402 | $14,366
Add effect of dilutive securities |  |  | 
Interest on convertible notes, net of tax | 207 | 362 | 536
Adjusted net income | $24,400 | $20,764 | $14,902
Denominator: |  |  | 
Weighted average basic common shares outstanding | 29,532,342 | 28,703,265 | 26,118,482
Dilutive effect of stock options and unvested common shares | 211,050 | 270,520 | 68,670
Dilutive effect of convertible notes | 329,946 | 705,134 | 1,237,374
Weighted average diluted common shares outstanding | 30,073,338 | 29,678,919 | 27,424,526


Question: What is the Weighted average diluted common shares outstanding for fiscal years 2019, 2018 and 2017 respectively?
Answer: 30,073,338, 29,678,919, 27,424,526
DEVELOPMENT OF EMPLOYEE NUMBERS BY SEGMENTS
By headcount1 as of closing date of 30/9
1 Excluding METRO China.
Table:
 | 2018 | 2019
METRO | 92,603 | 89,574
METRO Germany | 13,711 | 13,606
METRO Western Europe (excl.Germany) | 27,207 | 27,227
METRO Russia | 13,960 | 12,357
METRO Eastern Europe (excl.Russia) | 29,060 | 28,375
METRO Asia | 8,665 | 8,009
Others | 7,008 | 7,152
METROAG | 909 | 880
Total | 100,520 | 97,606


Question: When are the employee numbers by segments counted?
Answer: as of closing date of 30/9
Research and Development
Research and development expenses increased $24.2 million, or 31%, in 2019 as compared to 2018. The increase was principally due to the 2018 Reallocation of headcount from sales and marketing to research and development, as well as investments to maintain and improve the functionality of our products. As a result, we incurred increased employee-related costs of $16.3 million and increased overhead costs of $3.4 million.
Research and development expenses increased $15.0 million, or 24%, in 2018 as compared to 2017. The increase was principally due to the 2018 Reallocation of headcount from sales and marketing to research and development, as well as investments to maintain and improve the functionality of our products. As a result, we incurred increased employee-related costs of $12.1 million.
Table:
 |  | Year Ended December 31, | 
 | 2019 | 2018 | 2017
 |  | (dollars in thousands) | 
Research and development | $101,151 | $76,981 | $61,975
Percent of revenue | 17.5% | 14.3% | 12.9%


Question: How much were employee-related costs between 2017 and 2018?
Answer: $12.1 million
Results of Operations
Historically, revenues and earnings may or may not be representative of future operating results due to various economic and other factors. The following table sets forth the Consolidated Statements of Operations for the periods indicated (amounts in thousands):
(1) Fiscal years ended March 31, 2018 and 2017 adjusted due to the adoption of ASC 606.
Table:
 |  | Fiscal Years Ended March 31, | 
 | 2019 | 2018 | 2017
Net sales (1) | $1,382,818 | $1,200,181 | $757,338
Operating costs and expenses: |  |  | 
Cost of sales (1) | 924,276 | 860,744 | 571,944
Selling, general and administrative expenses | 202,642 | 173,620 | 107,658
Research and development (1) | 44,612 | 39,114 | 26,693
Restructuring charges | 8,779 | 14,843 | 5,404
(Gain) loss on write down and disposal of long-lived assets | 1,660 | (992) | 10,671
Total operating costs and expenses | 1,181,969 | 1,087,329 | 722,370
Operating income (1) | 200,849 | 112,852 | 34,968
Non-operating (income) expense: |  |  | 
Interest income | (2,035) | (809) | (24)
Interest expense | 21,239 | 32,882 | 39,755
Acquisition (gain) loss | — | (130,880) | —
Change in value of TOKIN options | — | — | (10,700)
Other (income) expense, net (1) | 11,214 | 24,592 | (3,871)
Income before income taxes and equity income (loss) from equity method investments (1) | 170,431 | 187,067 | 9,808
Income tax expense (benefit) (1) | (39,460) | 9,132 | 4,294
Income before equity income (loss) from equity method investments (1) | 209,891 | 177,935 | 5,514
Equity income (loss) from equity method investments | (3,304) | 76,192 | 41,643
Net income (1) | $206,587 | $254,127 | $47,157


Question: What was the change in Interest expense between 2017 and 2018?
Answer: -6873
Calculation: 32,882-39,755